| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9161914 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10729667 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166206 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10166205 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US10695303 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
| US8778365 | SEBELA IRELAND LTD | Topical compositions and methods for making and using same |
Jan, 2033
(8 years from now) | |
Naftin is owned by Sebela Ireland Ltd.
Naftin contains Naftifine Hydrochloride.
Naftin has a total of 6 drug patents out of which 0 drug patents have expired.
Naftin was authorised for market use on 27 June, 2013.
Naftin is available in gel;topical dosage forms.
Naftin can be used as treatment of fungal infections.
The generics of Naftin are possible to be released after 31 January, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 27, 2016 |
Drugs and Companies using NAFTIFINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 June, 2013
Treatment: Treatment of fungal infections
Dosage: GEL;TOPICAL
How can I launch a generic of NAFTIN before it's drug patent expiration?
More Information on Dosage
NAFTIN family patents
